These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29673058)

  • 21. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
    Jackups R; Canter C; Sweet SC; Mohanakumar T; Morris GP
    J Clin Apher; 2013 Aug; 28(4):301-8. PubMed ID: 23426730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosensitization and outcomes in pediatric heart transplantation.
    Mahle WT; Tresler MA; Edens RE; Rusconi P; George JF; Naftel DC; Shaddy RE;
    J Heart Lung Transplant; 2011 Nov; 30(11):1221-7. PubMed ID: 21821435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.
    Hachem RR; Kamoun M; Budev MM; Askar M; Ahya VN; Lee JC; Levine DJ; Pollack MS; Dhillon GS; Weill D; Schechtman KB; Leard LE; Golden JA; Baxter-Lowe L; Mohanakumar T; Tyan DB; Yusen RD
    Am J Transplant; 2018 Sep; 18(9):2285-2294. PubMed ID: 29687961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
    Senev A; Lerut E; Van Sandt V; Coemans M; Callemeyn J; Sprangers B; Kuypers D; Emonds MP; Naesens M
    Am J Transplant; 2019 Nov; 19(11):3100-3113. PubMed ID: 31062492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of virtual crossmatch (VXM) prediction of physical crossmatch (PXM) results of donor specific antibody (DSA) in routine pretransplant settings-a single-center experience.
    Olszowska-Zaremba N; Zagożdżon R; Gozdowska J
    Transpl Immunol; 2022 Jun; 72():101583. PubMed ID: 35314352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients.
    Zecher D; Bach C; Preiss A; Staudner C; Utpatel K; Evert M; Jung B; Bergler T; Böger CA; Spriewald BM; Banas B
    Transplantation; 2018 Jun; 102(6):969-977. PubMed ID: 29470350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens.
    Reinsmoen NL; Patel J; Mirocha J; Lai CH; Naim M; Ong G; Wang Q; Zhang X; Liou F; Yu Z; Kobashigawa J
    J Heart Lung Transplant; 2016 Feb; 35(2):165-72. PubMed ID: 26683810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
    Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
    Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
    Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
    Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
    Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
    Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.